Artwork

Innehåll tillhandahållet av BioTalk Unzipped. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av BioTalk Unzipped eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !

Insights from AAPS PharmSci 360 Live with Mark Arnold

29:49
 
Dela
 

Manage episode 447991301 series 3593861
Innehåll tillhandahållet av BioTalk Unzipped. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av BioTalk Unzipped eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.

In this episode of BioTalk Unzipped, host Gregory Austin and co-host Chad Briscoe engage with Dr. Mark Arnold, a distinguished bioanalytical thought leader. They discuss the impact of recent FDA regulations on drug development, the importance of community support through the Samaritan Purse charity, especially on recent hurricane victims, and the exciting advancements in RNA editing technologies. The conversation highlights the collaborative nature of the pharmaceutical industry and the drive behind bioanalytical work, emphasizing the ultimate goal of delivering effective therapies to patients.


Chapters

00:00 Introduction to BioTalk Unzipped at AAPS PharmSci 360

03:45 Samaritan's Purse Charity and Community Impact

05:16 Most impactful talk at AAPS?

11:50 Comparative Analysis of FDA and EU Regulations

17:37 The Drive Behind Bioanalytical Work

22:24 NEW NEWS! - Innovations in RNA Editing and Bioanalysis


Takeaways

  • ​The FDA's new rules on lab-developed tests could delay biomarker utilization in clinical trials.
  • ​Community support through charities like Samaritan's Purse is crucial during crises.
  • ​The importance of collaboration in advancing drug development and bioanalytical methods.
  • ​Innovations in RNA editing present new bioanalytical challenges.
  • ​The drive to help patients is a key motivator for professionals in the field.

Sound Bites

  • ​"I worked on that drug and there's a clear benefit."
  • ​"It's getting that new therapy to a patient."
  • ​"This is going to change and potentially delay biomarkers."

New News Story:

  • ​Wave sees RNA editing validation in early trial results

https://www.biopharmadive.com/news/wave-rna-editing-aatd-first-trial-data/729981/


How to reach us:

Please donate to: Samaritan’s Purse

https://www.samaritanspurse.org/


Mark Arnold

https://www.linkedin.com/in/markearnoldphd/

Blog - https://bioanalysisandbiomarkers.blogspot.com/

Dr. Chad Briscoe

https://www.linkedin.com/in/chadbriscoe/

Celerion - https://www.celerion.com/


Gregory Austin

https://www.linkedin.com/in/gregoryaustin1/

ECI - https://eci-rx.com /


Image Credits

  • ​AAPS
  continue reading

28 episoder

Artwork
iconDela
 
Manage episode 447991301 series 3593861
Innehåll tillhandahållet av BioTalk Unzipped. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av BioTalk Unzipped eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.

In this episode of BioTalk Unzipped, host Gregory Austin and co-host Chad Briscoe engage with Dr. Mark Arnold, a distinguished bioanalytical thought leader. They discuss the impact of recent FDA regulations on drug development, the importance of community support through the Samaritan Purse charity, especially on recent hurricane victims, and the exciting advancements in RNA editing technologies. The conversation highlights the collaborative nature of the pharmaceutical industry and the drive behind bioanalytical work, emphasizing the ultimate goal of delivering effective therapies to patients.


Chapters

00:00 Introduction to BioTalk Unzipped at AAPS PharmSci 360

03:45 Samaritan's Purse Charity and Community Impact

05:16 Most impactful talk at AAPS?

11:50 Comparative Analysis of FDA and EU Regulations

17:37 The Drive Behind Bioanalytical Work

22:24 NEW NEWS! - Innovations in RNA Editing and Bioanalysis


Takeaways

  • ​The FDA's new rules on lab-developed tests could delay biomarker utilization in clinical trials.
  • ​Community support through charities like Samaritan's Purse is crucial during crises.
  • ​The importance of collaboration in advancing drug development and bioanalytical methods.
  • ​Innovations in RNA editing present new bioanalytical challenges.
  • ​The drive to help patients is a key motivator for professionals in the field.

Sound Bites

  • ​"I worked on that drug and there's a clear benefit."
  • ​"It's getting that new therapy to a patient."
  • ​"This is going to change and potentially delay biomarkers."

New News Story:

  • ​Wave sees RNA editing validation in early trial results

https://www.biopharmadive.com/news/wave-rna-editing-aatd-first-trial-data/729981/


How to reach us:

Please donate to: Samaritan’s Purse

https://www.samaritanspurse.org/


Mark Arnold

https://www.linkedin.com/in/markearnoldphd/

Blog - https://bioanalysisandbiomarkers.blogspot.com/

Dr. Chad Briscoe

https://www.linkedin.com/in/chadbriscoe/

Celerion - https://www.celerion.com/


Gregory Austin

https://www.linkedin.com/in/gregoryaustin1/

ECI - https://eci-rx.com /


Image Credits

  • ​AAPS
  continue reading

28 episoder

Alla avsnitt

×
 
Loading …

Välkommen till Player FM

Player FM scannar webben för högkvalitativa podcasts för dig att njuta av nu direkt. Den är den bästa podcast-appen och den fungerar med Android, Iphone och webben. Bli medlem för att synka prenumerationer mellan enheter.

 

Snabbguide